{
    "clinical_study": {
        "@rank": "146516", 
        "brief_summary": {
            "textblock": "To estimate the differences in parameters of antiviral activity and safety between a control\n      regimen of indinavir in combination with DMP 266 and an experimental regimen of higher-dose\n      indinavir in combination with lower-dose DMP 266 after sixteen weeks of dosing, in protease\n      inhibitor- and non-nucleoside reverse transcriptase inhibitor-naive, HIV-1 seropositive\n      patients.\n\n      It is hypothesized that after 16 weeks of randomized treatment with either the control or\n      experimental regimen that:\n\n        1. The observed proportion of patients with serum viral RNA < 400 copies/ml in the\n           experimental and control regimen will be similar and will continue to be so after 48\n           weeks.\n\n        2. The safety profiles of the two groups will be similar, judged by the incidence of\n           serious, drug-related adverse experiences and the incidence of events of specific\n           interest (e.g., nephrolithiasis, hyperbilirubinemia, nausea/vomiting, rash, and\n           CNS-related symptoms) and will continue to be so after 48 weeks.\n\n        3. The two groups will be similar with respect to changes from baseline in serum viral RNA\n           and CD4 counts and will continue to be so after 48 weeks."
        }, 
        "brief_title": "The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is hypothesized that after 16 weeks of randomized treatment with either the control or\n      experimental regimen that:\n\n        1. The observed proportion of patients with serum viral RNA < 400 copies/ml in the\n           experimental and control regimen will be similar and will continue to be so after 48\n           weeks.\n\n        2. The safety profiles of the two groups will be similar, judged by the incidence of\n           serious, drug-related adverse experiences and the incidence of events of specific\n           interest (e.g., nephrolithiasis, hyperbilirubinemia, nausea/vomiting, rash, and\n           CNS-related symptoms) and will continue to be so after 48 weeks.\n\n        3. The two groups will be similar with respect to changes from baseline in serum viral RNA\n           and CD4 counts and will continue to be so after 48 weeks.\n\n      Patients are randomized to one of two regimens: a control regimen of indinavir plus DMP 266\n      or an experimental regimen of indinavir plus DMP 266, each at different doses than in the\n      control regimen."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV-1 seropositive status.\n\n          -  CD4 count >= 100 cells/mm3.\n\n          -  Serum viral RNA levels >= 10,000 copies/ml.\n\n        Exclusion Criteria\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior protease inhibitor therapy.\n\n          -  Prior non-nucleoside reverse transcriptase inhibitor therapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "80", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002387", 
            "org_study_id": "246K", 
            "secondary_id": "067-00"
        }, 
        "intervention": [
            {
                "intervention_name": "Indinavir sulfate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Efavirenz", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "HIV Protease Inhibitors", 
                "Indinavir", 
                "Efavirenz", 
                "Reverse Transcriptase Inhibitors"
            ]
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "Drug Administration Schedule", 
            "HIV Protease Inhibitors", 
            "Indinavir", 
            "Reverse Transcriptase Inhibitors", 
            "Anti-HIV Agents", 
            "efavirenz"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "921036329"
                    }, 
                    "name": "UCSD Treatment Ctr / Dept of Medicine & Pediatrics"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94110"
                    }, 
                    "name": "San Francisco Gen Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80262"
                    }, 
                    "name": "Univ of Colorado / Health Science Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Honolulu", 
                        "country": "United States", 
                        "state": "Hawaii", 
                        "zip": "96816"
                    }, 
                    "name": "Hawaii AIDS Clinical Trial Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush Med Ctr / Section of Infectious Diseases"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Beth Israel Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stony Brook", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "117948153"
                    }, 
                    "name": "Univ Hosp / SUNY at Stony Brook / AIDS TMT Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island", 
                        "zip": "02906"
                    }, 
                    "name": "Brown Univ / Miriam Hosp"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Multicenter, Open, Randomized, Forty-Eight-Week, Pilot Study to Evaluate the Activity, Safety, and Pharmacokinetics of Indinavir Sulfate, 1200 Mg q 12h and DMP 266, 300 Mg q 12h Versus Indinavir Sulfate, 1000 Mg q 8h and DMP 266, 600 Mg q.h.s.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002387"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 1999"
    }, 
    "geocoordinates": {
        "Beth Israel Hosp": "42.358 -71.06", 
        "Brown Univ / Miriam Hosp": "41.824 -71.413", 
        "Hawaii AIDS Clinical Trial Unit": "21.307 -157.858", 
        "Rush Med Ctr / Section of Infectious Diseases": "41.878 -87.63", 
        "San Francisco Gen Hosp": "37.775 -122.419", 
        "UCSD Treatment Ctr / Dept of Medicine & Pediatrics": "32.715 -117.157", 
        "Univ Hosp / SUNY at Stony Brook / AIDS TMT Unit": "40.926 -73.141", 
        "Univ of Colorado / Health Science Ctr": "39.739 -104.985"
    }
}